Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Cash from Operations (2023 - 2024)

Sagimet Biosciences has reported Cash from Operations over the past 2 years, most recently at 11024000.0 for Q4 2024.

  • Quarterly results put Cash from Operations at 11024000.0 for Q4 2024, down 55.64% from a year ago — trailing twelve months through Dec 2024 was 42435000.0 (down 78.55% YoY), and the annual figure for FY2025 was 45650000.0, down 7.58%.
  • Cash from Operations for Q4 2024 was 11024000.0 at Sagimet Biosciences, up from 19569000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for SGMT hit a ceiling of 3879000.0 in Q3 2023 and a floor of 19569000.0 in Q3 2024.